Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity.
BMAL1
insulin treatment
metabolism
obesity
triple-negative breast cancer
tumor suppressor
Journal
Trends in molecular medicine
ISSN: 1471-499X
Titre abrégé: Trends Mol Med
Pays: England
ID NLM: 100966035
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
20
01
2020
revised:
28
01
2020
accepted:
29
01
2020
entrez:
12
4
2020
pubmed:
12
4
2020
medline:
12
4
2020
Statut:
ppublish
Résumé
Factors of metabolic syndrome including hyperinsulinemia and obesity are well known to increase the risk of cancer incidence and progression. In a recent iScience article, Ramos et al. demonstrate a novel tumor-suppressor role of the circadian transcription factor BMAL1 in triple-negative breast cancer (TNBC) specifically under conditions of hyperinsulinemia.
Identifiants
pubmed: 32277929
pii: S1471-4914(20)30042-3
doi: 10.1016/j.molmed.2020.01.014
pii:
doi:
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
354-356Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.